Leukotriene Receptor

LTB4-IN-1 is a selective leukotriene receptor inhibitor, effectively blocking leukotriene B4 synthesis with an IC50 of 70 nM. This compound serves as a valuable tool for research in inflammation and immune response, potentially aiding in the investigation of leukotriene-mediated pathophysiological conditions. Its application can extend to studies focused on cellular signaling and therapeutic interventions targeting leukotriene pathways.

Pranlukast hemihydrate is a potent and selective competitive antagonist of peptide leukotrienes, targeting the leukotriene receptor. It effectively inhibits the binding of [3H]LTE4, [3H]LTD4, and [3H]LTC4 to lung membranes, with inhibition constants (Kis) of 0.63±0.11 nM, 0.99±0.19 nM, and 5640±680 nM, respectively. This compound is valuable in research applications related to inflammation and allergic responses, making it a useful tool for studying leukotriene signaling pathways.